BUZZ-Lilly rides weight-loss drug wave, set for eighth straight yearly gain

** Weight loss drugmaker Eli Lilly's LLY.N shares have risen about 33% this year - set for the eighth successive year of gains

** LLY, already the world's most valuable healthcare company, is set to add another $180 billion to its market cap this year

** LLY's popular diabetes and weight loss drugs - Mounjaro and Zepbound - compete with Danish drugmaker Novo Nordisk's NOVOb.CO Ozempic and Wegovy in a market poised to be worth about $150 billion by the early 2030s

** Demand for the drugs, collectively known as GLP-1 agonists, has outpaced supply for most of this year

** But Novo stock has declined about 11% this year - set to break a five-year winning streak

** Both LLY and Novo had what Wall Street termed a "soft Q3", with LLY posting Mounjaro and Zepbound revenues below analyst expectations

** BMO Capital Markets analysts believe LLY and Novo should expand manufacturing and push for more scrutiny of compounded pharmacies to maintain growth

** " ... both Lilly and Novo will need to engage in more targeted sales campaigns to engage patients who are not first adopters," BMO analysts say

** Tema Obesity and Cardiometabolic ETF HRTS.O - which includes both Lilly and Novo - has declined 5% this year

(Reporting by Bhanvi Satija in Bengaluru)

((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))